Management and treatment optimization of patients with mild to moderate ulcerative colitis

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. doi: 10.1016/S0140-6736(16)32126-2
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Bala M, et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13(9):1135–1140. doi: 10.1002/ibd.20165
   PubMed Web of Science ®Google Scholar
• Lopez A, Pouillon L, Beaugerie L, et al. Colorectal cancer prevention in patients with ulcerative colitis. Best Pract Res Clin Gastroenterol. 2018;32–33:103–109. doi: 10.1016/j.bpg.2018.05.010
   PubMed Web of Science ®Google Scholar
• Yashiro M. Ulcerative colitis-associated colorectal cancer. World J Gastroenterol. 2014;20(44):16389–16397. doi: 10.3748/wjg.v20.i44.16389
   PubMed Web of Science ®Google Scholar
• Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7(4):322–337. doi: 10.1016/j.crohns.2013.01.010
   PubMed Web of Science ®Google Scholar
• Alatab S, Sepanlou SG, Ikuta K, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30. doi: 10.1016/S2468-1253(19)30333-4
   PubMed Web of Science ®Google Scholar
• Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504–1517. doi: 10.1053/j.gastro.2004.01.063
   PubMed Web of Science ®Google Scholar
• Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713–1725. doi: 10.1056/NEJMra1102942
   PubMed Web of Science ®Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749–753. doi: 10.1136/gut.2005.082909
   PubMed Web of Science ®Google Scholar
• Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649–670. doi: 10.1093/ecco-jcc/jjx008
   PubMed Web of Science ®Google Scholar
• D’Amico F, Fiorino G, Furfaro F, et al. Patient’s profiling for therapeutic management of inflammatory bowel disease: a tailored approach. Expert Rev Gastroenterol Hepatol. 2020;14(9):765–773. doi: 10.1080/17474124.2020.1772057
   PubMed Web of Science ®Google Scholar
• Gros B, Kaplan GG. Ulcerative Colitis in Adults: A Review. JAMA. 2023;330(10):951. doi: 10.1001/jama.2023.15389
   PubMed Web of Science ®Google Scholar
• Segal JP, LeBlanc J-F, Hart AL. Ulcerative colitis: an update. Clin Med. 2021;21(2):135–139. doi: 10.7861/clinmed.2021-0080
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Peyrin-Biroulet L. Positioning therapies in ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(6):1280–1290.e1. doi: 10.1016/j.cgh.2020.01.017
   PubMed Web of Science ®Google Scholar
• Walsh AJ, Bryant RV, Travis SPL. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol. 2016;13(10):567–579. doi: 10.1038/nrgastro.2016.128
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987;317(26):1625–1629. doi: 10.1056/NEJM198712243172603
   PubMed Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone in Ulcerative Colitis. BMJ. 1955;2(4947):1041–1048. doi: 10.1136/bmj.2.4947.1041
   PubMed Web of Science ®Google Scholar
• Travis SPL, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the ulcerative colitis endoscopic Index of severity (UCEIS). Gut. 2012;61(4):535–542. doi: 10.1136/gutjnl-2011-300486
   PubMed Web of Science ®Google Scholar
• Walmsley RS, Ayres RCS, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43(1):29–32. doi: 10.1136/gut.43.1.29
   PubMed Web of Science ®Google Scholar
• D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763–786. doi: 10.1053/j.gastro.2006.12.038
   PubMed Web of Science ®Google Scholar
• Ko CW, Singh S, Feuerstein JD, et al. American gastroenterological association institute guideline on the management of mild-moderate ulcerative colitis. Gastroenterology. 2019;156(3):748–764. doi: 10.1053/j.gastro.2018.12.009
   PubMed Web of Science ®Google Scholar
• Lamb CA, Kennedy NA, Raine T, et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106. doi: 10.1136/gutjnl-2019-318484
   PubMed Web of Science ®Google Scholar
• Caron B, Jairath V, D’Amico F, et al. Definition of mild to moderate ulcerative colitis in clinical trials: a systematic literature review. UEG J. 2022;10(8):854–867. doi: 10.1002/ueg2.12283
   PubMed Web of Science ®Google Scholar
• Research C for DE and. Ulcerative colitis: developing drugs for treatment [Internet]. FDA; 2022 [cited 2023 Sep 12]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ulcerative-colitis-developing-drugs-treatment.
   Google Scholar
• Caron B, Jairath V, D’Amico F, et al. International consensus on definition of mild-to-moderate ulcerative colitis disease activity in adult patients. Medicina. 2023;59(1):183. doi: 10.3390/medicina59010183
   PubMedGoogle Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338. doi: 10.1038/ajg.2015.233
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi: 10.1053/j.gastro.2020.12.031
   PubMed Web of Science ®Google Scholar
• Le Berre C, Ananthakrishnan AN, Danese S, et al. Ulcerative colitis and Crohn’s disease have similar burden and goals for treatment. Clin Gastroenterol Hepatol. 2020;18(1):14–23. doi: 10.1016/j.cgh.2019.07.005
   PubMed Web of Science ®Google Scholar
• Torres J, Billioud V, Sachar DB, et al. Ulcerative colitis as a progressive disease: the forgotten evidence: inflammatory bowel diseases. Inflamm Bowel Dis. 2012;18(7):1356–1363. doi: 10.1002/ibd.22839
   PubMed Web of Science ®Google Scholar
• Ochsenkuhn T, D’Haens G. Current misunderstandings in the management of ulcerative colitis. Gut. 2011;60(9):1294–1299. doi: 10.1136/gut.2010.218180
   PubMed Web of Science ®Google Scholar
• Gordon IO, Abushamma S, Kurowski JA, et al. Paediatric ulcerative colitis is a fibrotic disease and is linked with chronicity of inflammation. J Crohn’s & Colitis. 2022;16(5):804–821. doi: 10.1093/ecco-jcc/jjab216
   PubMed Web of Science ®Google Scholar
• Gordon IO, Agrawal N, Willis E, et al. Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation. Aliment Pharmacol Ther. 2018;47(7):922–939. doi: 10.1111/apt.14526
   PubMed Web of Science ®Google Scholar
• Laurain P-A, Guillo L, D’Amico F, et al. Incidence of and risk factors for colorectal strictures in ulcerative colitis: a multicenter study. Clin Gastroenterol Hepatol. 2021;19(9):1899–1905.e1. doi: 10.1016/j.cgh.2021.01.028
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2012;61(2):241–247. doi: 10.1136/gutjnl-2011-300049
   PubMed Web of Science ®Google Scholar
• Rao SSC, Read NW, Davison PA, et al. Anorectal sensitivity and responses to rectal distention in patients with ulcerative colitis. Gastroenterology. 1987;93(6):1270–1275. doi: 10.1016/0016-5085(87)90255-1
   PubMed Web of Science ®Google Scholar
• Solitano V, D’Amico F, Zacharopoulou E, et al. Early intervention in ulcerative colitis: ready for prime time? JCM. 2020;9(8):2646. doi: 10.3390/jcm9082646
   Google Scholar
• Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol. 2010;105(12):2617–2625. doi: 10.1038/ajg.2010.345
   PubMed Web of Science ®Google Scholar
• Ma C, Beilman CL, Huang VW, et al. Similar clinical and surgical outcomes achieved with early compared to late anti-TNF induction in mild-to-moderate ulcerative colitis: a retrospective cohort study. Can J Gastroenterol Hepatol. 2016;2016:1–9. doi: 10.1155/2016/2079582
   Web of Science ®Google Scholar
• Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2–17. doi: 10.1093/ecco-jcc/jjab178
   PubMed Web of Science ®Google Scholar
• Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2): CD000543. doi: 10.1002/14651858.CD000543
   PubMed Web of Science ®Google Scholar
• Wang Y, Parker CE, Bhanji T, et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;4. CD000543.
   Google Scholar
• Nikfar S, Rahimi R, Rezaie A, et al. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci. 2009;54(6):1157–1170. doi: 10.1007/s10620-008-0481-x
   PubMed Web of Science ®Google Scholar
• Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:CD000543.
   PubMed Web of Science ®Google Scholar
• Murray A, Nguyen TM, Parker CE, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(8). 8 CD000544. doi: 10.1002/14651858.CD000544.pub5.
   Google Scholar
• Ford AC, Achkar J-P, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):601–616. doi: 10.1038/ajg.2011.67
   PubMed Web of Science ®Google Scholar
• Williams C, Panaccione R, Ghosh S, et al. Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol. 2011;4(4):237–248. doi: 10.1177/1756283X11405250
   PubMedGoogle Scholar
• Solitano V, D’Amico F, Fiorino G, et al. Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. JCM. 2020;9(9):2905. doi: 10.3390/jcm9092905
   Google Scholar
• Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing - ASCEND I and II combined analysis: Randomised clinical trial: mucosal healing with delayed-release mesalazine. Aliment Pharmacol Ther. 2011;33(6):672–678. doi: 10.1111/j.1365-2036.2010.04575.x
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009;137(6):1934–1943.e3. doi: 10.1053/j.gastro.2009.08.069
   PubMed Web of Science ®Google Scholar
• Buckland A, Bodger K. The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. Aliment Pharmacol Ther. 2008;28(11–12):1287–1296. doi: 10.1111/j.1365-2036.2008.03856.x
   PubMed Web of Science ®Google Scholar
• Louis E, Paridaens K, Al Awadhi S, et al. Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. BMJ Open Gastroenterol. 2022;9(1):e000853. doi: 10.1136/bmjgast-2021-000853
   PubMed Web of Science ®Google Scholar
• Rubin DT, Bradette M, Gabalec L, et al. Ulcerative colitis remission status after induction with mesalazine predicts maintenance outcomes: the MOMENTUM trial. J Crohns Colitis. 2016;10(8):925–933. doi: 10.1093/ecco-jcc/jjw049
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Umegae S, Matsumoto K. High-dose mesalazine treatment for ulcerative colitis patients who relapse under low-dose maintenance therapy. Digestive Liver Dis. 2011;43(5):386–390. doi: 10.1016/j.dld.2010.11.016
   Web of Science ®Google Scholar
• Pica R, Cassieri C, Cocco A, et al. A randomized trial comparing 4.8 vs. 2.4g/day of oral mesalazine for maintenance of remission in ulcerative colitis. Digestive Liver Dis. 2015;47(11):933–937. doi: 10.1016/j.dld.2015.07.011
   Web of Science ®Google Scholar
• Sehgal P, Colombel J-F, Aboubakr A, et al. Systematic review: safety of mesalazine in ulcerative colitis. Aliment Pharmacol Ther. 2018;47(12):1597–1609. doi: 10.1111/apt.14688
   PubMed Web of Science ®Google Scholar
• Gisbert JP, González-Lama Y, Maté J. 5-aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007;13(5):629–638. doi: 10.1002/ibd.20099
   PubMed Web of Science ®Google Scholar
• Guillo L, D’Amico F, Achit H, et al. Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: what the gastroenterologist should know. Dig Liver Dis. 2021;53(6):691–696. doi: 10.1016/j.dld.2021.01.015
   PubMedGoogle Scholar
• Moss JG, Parry CM, Holt RCL, et al. 5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review. Eur J Med Res. 2022;27(1):61. doi: 10.1186/s40001-022-00687-y
   PubMed Web of Science ®Google Scholar
• Haralambou G, Teirstein AS, Gil J, et al. Bronchiolitis obliterans in a patient with ulcerative colitis receiving mesalamine. Mt Sinai J Med. 2001;68(6):384–388.
   PubMedGoogle Scholar
• Zhang Y, Luo L, Liu X, et al. Mesalazine-induced eosinophilic pneumonia with bone marrow infiltration: a case report and literature review. TCRM. 2016;975:975. doi: 10.2147/TCRM.S107012
   Google Scholar
• Inoue M, Horita N, Kimura N, et al. Three cases of mesalazine-induced pneumonitis with eosinophilia. Respir Investig. 2014;52(3):209–212. doi: 10.1016/j.resinv.2013.12.002
   PubMedGoogle Scholar
• Ferrusquía J, Pérez-Martínez I, Gómez de la Torre R, et al. Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity. World J Gastroenterol. 2015;21(13):4069–4077. doi: 10.3748/wjg.v21.i13.4069
   PubMed Web of Science ®Google Scholar
• Testa A, Castiglione F, Nardone OM, et al. Adherence in ulcerative colitis: an overview. Patient Prefer Adherence. 2017;11:297–303. doi: 10.2147/PPA.S127039
   PubMed Web of Science ®Google Scholar
• Feagan BG, MacDonald JK. Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18(9):1785–1794. doi: 10.1002/ibd.23024
   PubMed Web of Science ®Google Scholar
• Kruis W, Kiudelis G, Racz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut. 2009;58(2):233–240. doi: 10.1136/gut.2008.154302
   PubMed Web of Science ®Google Scholar
• Flourié B, Hagège H, Tucat G, et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther. 2013;37(8):767–775. doi: 10.1111/apt.12266
   PubMed Web of Science ®Google Scholar
• Raedler A, Behrens C, Bias P. Mesalazine (5‐aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis – results from a randomized‐controlled trial. Aliment Pharmacol Ther. 2004;20(11–12):1353–1363. doi: 10.1111/j.1365-2036.2004.02282.x
   PubMed Web of Science ®Google Scholar
• Keil R, Wasserbauer M, Zádorová Z, et al. Adherence, risk factors of non-adherence and patient’s preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study. Scand J Gastroenterol. 2018;53(4):459–465. doi: 10.1080/00365521.2018.1451915
   PubMed Web of Science ®Google Scholar
• Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis. 2005;11(5):421–427. doi: 10.1097/01.MIB.0000158386.25660.1e
   PubMed Web of Science ®Google Scholar
• Angelucci E, Malesci A, Danese S. Budesonide: teaching an old dog new tricks for inflammatory bowel disease treatment. Curr Med Chem. 2008;15(24):2527–2535. doi: 10.2174/092986708785909049
   PubMed Web of Science ®Google Scholar
• Sriram A, Tangirala S, Atmakuri S, et al. Budding multi-matrix technology—a retrospective approach, deep insights, and future perspectives. AAPS Pharm Sci Tech. 2021;22(8):264. doi: 10.1208/s12249-021-02133-4
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5(1):95–102. doi: 10.1016/j.cgh.2006.10.025
   PubMed Web of Science ®Google Scholar
• Schreiber S, Hanauer SB, Sandborn WJ, et al. Time to symptom resolution in ulcerative colitis with multimatrix mesalazine treatment: a pooled analysis. J Crohns Colitis. 2020;14(9):1274–1281. doi: 10.1093/ecco-jcc/jjaa041
   PubMed Web of Science ®Google Scholar
• Yarlas A, Willian MK, Nag A. The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine. Qual Life Res. 2021;30(7):1925–1938. doi: 10.1007/s11136-021-02787-4
   PubMed Web of Science ®Google Scholar
• Yarlas A, D’Haens G, Willian MK, et al. Health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis and remission status following short-term and long-term treatment with Multimatrix Mesalamine: a prospective, open-label study. Inflamm Bowel Dis. 2018;24(2):450–463. doi: 10.1093/ibd/izx041
   PubMed Web of Science ®Google Scholar
• Yamamoto-Furusho JK, Parra-Holguín NN. Real-world experience with MMX mesalazine use in Mexican patients with ulcerative colitis at two tertiary care centers. Rev Gastroenterol Mex (Engl Ed). 2021;S0375-0906(21):00058–6.
   Google Scholar
• Van Bodegraven A, Boer R, Lourens J, et al. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment Pharmacol Ther. 1996;10(3):327–332. doi: 10.1111/j.0953-0673.1996.00327.x
   PubMed Web of Science ®Google Scholar
• Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;20(1): CD004115.
   Google Scholar
• Nguyen NH, Fumery M, Dulai PS, et al. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 2018;3(11):742–753. doi: 10.1016/S2468-1253(18)30231-0
   PubMed Web of Science ®Google Scholar
• Barberio B, Segal JP, Quraishi MN, et al. Efficacy of oral, topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and network meta-analysis. J Crohns Colitis. 2021;15(7):1184–1196. doi: 10.1093/ecco-jcc/jjab010
   PubMed Web of Science ®Google Scholar
• Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005;54(7):960–965. doi: 10.1136/gut.2004.060103
   PubMed Web of Science ®Google Scholar
• Probert CSJ, Dignass AU, Lindgren S, et al. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. J Crohn’s & Colitis. 2014;8(3):200–207. doi: 10.1016/j.crohns.2013.08.007
   PubMed Web of Science ®Google Scholar
• Singh S, Feuerstein JD, Binion DG, et al. AGA Technical review on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156(3):769–808.e29. doi: 10.1053/j.gastro.2018.12.008
   PubMed Web of Science ®Google Scholar
• Paoluzi P, D’Albasio G, Pera A, et al. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Digestive Liver Dis. 2002;34(11):787–793. doi: 10.1016/S1590-8658(02)80072-X
   Web of Science ®Google Scholar
• Yokoyama H, Takagi S, Kuriyama S, et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis. 2007;13(9):1115–1120. doi: 10.1002/ibd.20158
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on Diagnosis and management of ulcerative colitis. Part 2. Current Management J Crohns Colitis. 2017;11(7):769–784. doi: 10.1093/ecco-jcc/jjx009
   PubMed Web of Science ®Google Scholar
• Cross RK. Safety considerations with the use of corticosteroids and biologic therapies in mild-to-moderate ulcerative colitis: inflammatory bowel diseases. Inflamm Bowel Dis. 2017;23(10):1689–1701. doi: 10.1097/MIB.0000000000001261
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012;143(5):1218–1226.e2. doi: 10.1053/j.gastro.2012.08.003
   PubMed Web of Science ®Google Scholar
• Travis SPL, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014;63(3):433–441. doi: 10.1136/gutjnl-2012-304258
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Danese S, D’Haens G, et al. Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther. 2015;41(5):409–418. doi: 10.1111/apt.13076
   PubMed Web of Science ®Google Scholar
• Rubin DT, Cohen RD, Sandborn WJ, et al. Budesonide multimatrix is efficacious for mesalamine-refractory, mild to moderate ulcerative colitis: a randomised, placebo-controlled trial. J Crohns Colitis. 2017;11(7):785–791. doi: 10.1093/ecco-jcc/jjx032
   PubMed Web of Science ®Google Scholar
• De Cassan C, Fiorino G, Danese S. Second-generation corticosteroids for the treatment of Crohn’s disease and ulcerative colitis: more effective and less side effects? Dig Dis. 2012;30(4):368–375. doi: 10.1159/000338128
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Travis S, Danese S, et al. Budesonide MMX for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis. J Crohns Colitis. 2015;9(9):738–746. doi: 10.1093/ecco-jcc/jjv101
   PubMed Web of Science ®Google Scholar
• Danese S, Hart A, Dignass A, et al. A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®mmx®) for active, mild-to-moderate ulcerative colitis. United Eur Gastroenterol J. 2019;7(9):1171–1182. doi: 10.1177/2050640619864848
   PubMed Web of Science ®Google Scholar
• Maconi G, Mezzina N, Landi S, et al. Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: a real-life experience. United Eur Gastroenterol J. 2019;7(9):1164–1170. doi: 10.1177/2050640619864257
   PubMed Web of Science ®Google Scholar
• Greenberg S, Herfarth HH, Barnes EL. Predictors of inadequate response to budesonide multimatrix in real-world patients with ulcerative colitis. Inflamm Intest Dis. 2019;4(3):115–122. doi: 10.1159/000501004
   PubMedGoogle Scholar
• Crispino P, Pica R, Unim H, et al. Efficacy of mesalazine or beclomethasone dipropionate enema or their combination in patients with distal active ulcerative colitis. Eur Rev Med Pharmacol Sci. 2015;19(15):2830–2837.
   PubMed Web of Science ®Google Scholar
• Caron B, Sandborn WJ, Panaccione R, et al. Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review. J Crohn’s & Colitis. 2022;16(6):922–930. doi: 10.1093/ecco-jcc/jjab218
   PubMed Web of Science ®Google Scholar
• D’Arienzo A, Manguso F, Castiglione GN, et al. Beclomethasone dipropionate (3 mg) enemas combined with oral 5-ASA (2.4 g) in the treatment of ulcerative colitis not responsive to oral 5-ASA alone. Ital J Gastroenterol Hepatol. 1998;30(3):254–257.
   PubMedGoogle Scholar
• Mulder CJ, Fockens P, Meijer JW, et al. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol. 1996;8(6):549–554. doi: 10.1097/00042737-199606000-00010
   PubMed Web of Science ®Google Scholar
• Holko P, Kawalec P, Sajak-Szczerba M, et al. Out-of-pocket expenses of patients with inflammatory bowel disease: a comparison of patient-reported outcomes across 12 European countries. Eur J Health Econ. 2023;24(7):1073–1083. doi: 10.1007/s10198-022-01536-9
   PubMed Web of Science ®Google Scholar
• Danese S, Banerjee R, Cummings JF, et al. Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i support therapy–access to rapid treatment (iSTART) approach. Intest Res. 2018;16(4):522–528. doi: 10.5217/ir.2018.00073
   PubMed Web of Science ®Google Scholar
• D’Amico F, Magro F, Caron B, et al. iSTART-II: an update on the i support therapy–access to rapid treatment (iSTART) approach for patient-centered therapy in mild-to-moderate ulcerative colitis. J Clin Med. 2023;12(3):1142. doi: 10.3390/jcm12031142
   PubMed Web of Science ®Google Scholar
• Siegel CA. Refocusing IBD patient management: personalized, proactive, and patient-centered care. Am J Gastroenterol. 2018;113(10):1440–1443. doi: 10.1038/s41395-018-0246-x
   PubMed Web of Science ®Google Scholar
• Johnson LC, Melmed GY, Nelson EC, et al. Fostering collaboration through creation of an IBD learning health system. Am J Gastroenterol. 2017;112(3):406–408. doi: 10.1038/ajg.2017.9
   PubMed Web of Science ®Google Scholar
• Robinson A, Thompson DG, Wilkin D, et al. Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet. 2001;358(9286):976–981. doi: 10.1016/S0140-6736(01)06105-0
   PubMed Web of Science ®Google Scholar
• Cross RK, Cheevers N, Rustgi A, et al. Randomized, controlled trial of home Telemanagement in patients with ulcerative colitis (UC HAT). Inflamm Bowel Dis. 2012;18(6):1018–1025. doi: 10.1002/ibd.21795
   PubMed Web of Science ®Google Scholar
• Moshkovska T, Stone MA, Smith RM, et al. Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial. Inflamm Bowel Dis. 2011;17(9):1874–1881. doi: 10.1002/ibd.21570
   PubMed Web of Science ®Google Scholar
• Majidova K, Handfield J, Kafi K, et al. Role of digital health and Artificial Intelligence in inflammatory bowel disease: a scoping review. Genes. 2021;12(10):1465. doi: 10.3390/genes12101465
   PubMed Web of Science ®Google Scholar
• Gordon M, Sinopoulou V, Lakunina S, et al. Remote care through telehealth for people with inflammatory bowel disease. Cochrane Database Syst Rev. 2023;5(5): CD014821. doi: 10.1002/14651858.CD014821.pub2
   Google Scholar
• Del Hoyo J, Millán M, Garrido-Marín A, et al. Are we ready for telemonitoring inflammatory bowel disease? A review of advances, enablers, and barriers. World J Gastroenterol. 2023;29(7):1139–1156. doi: 10.3748/wjg.v29.i7.1139
   PubMed Web of Science ®Google Scholar
• Storan D, Lavelle J, Burke A-M, et al. Satisfaction with telemedicine-delivered inflammatory bowel disease care depends on disease activity, personality and economic factors. Frontline Gastroenterol. 2023;14(2):132–137. doi: 10.1136/flgastro-2022-102198
   PubMed Web of Science ®Google Scholar
• Pedersen N, Thielsen P, Martinsen L, et al. eHealth: individualization of mesalazine treatment through a self-managed web-based Solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2014;20(12):2276–2285. doi: 10.1097/MIB.0000000000000199
   PubMed Web of Science ®Google Scholar
• de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, et al. Telemedicine for management of inflammatory bowel disease (myIbdcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017;390(10098):959–968. doi: 10.1016/S0140-6736(17)31327-2
   PubMed Web of Science ®Google Scholar
• Östlund I, Werner M, Karling P. Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease. Scand J Gastroenterol. 2021;56(1):38–45. doi: 10.1080/00365521.2020.1854342
   PubMed Web of Science ®Google Scholar
• D’Amico F, Bonovas S, Danese S, et al. Review article: faecal calprotectin and histologic remission in ulcerative colitis. Aliment Pharmacol Ther. 2020;51(7):689–698. doi: 10.1111/apt.15662
   PubMed Web of Science ®Google Scholar
• D’Amico F, Nancey S, Danese S, et al. A practical Guide for faecal calprotectin measurement: myths and realities. J Crohns Colitis. 2021;15(1):152–161. doi: 10.1093/ecco-jcc/jjaa093
   PubMed Web of Science ®Google Scholar
• Kristensen V, Malmstrøm GH, Skar V, et al. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure. Scand J Gastroenterol. 2016;51(5):548–555. doi: 10.3109/00365521.2015.1117650
   PubMed Web of Science ®Google Scholar
• Lasson A, Stotzer P-O, Öhman L, et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohn’s & Colitis. 2014;S1873994614001858. doi: 10.1016/j.crohns.2014.06.002
   Web of Science ®Google Scholar
• CalproSmart Office [Internet]. [cited 2023 Aug 26]. Available from: https://www.svarlifescience.com/products/cal220.
   Google Scholar
• Ibdoc® by BÜHLMANN | monitor IBD | calprotectin home test [Internet]. [cited 2023 Aug 26]. Available from: https://www.ibdoc.net/.
   Google Scholar
• GmbH P QuantOn cal® [Internet]. Patient-oriented diagnostics - anytime & anywhere – preventis GmbH. [cited 2023 Aug 26]. Available from: https://preventis.com/en/products/quanton-cal.
   Google Scholar
• Solitano V, Alfarone L, D’Amico F, et al. IBD goes home: from telemedicine to self-administered advanced therapies. Expert Opin Biol Ther. 2022;22(1):17–29. doi: 10.1080/14712598.2021.1942833
   PubMed Web of Science ®Google Scholar
• Haisma S-M, Galaurchi A, Almahwzi S, et al. Head-to-head comparison of three stool calprotectin tests for home use. PLoS One. 2019;14(4):e0214751. doi: 10.1371/journal.pone.0214751
   PubMed Web of Science ®Google Scholar
• D’Amico F, Netter P, Baumann C, et al. Setting up a virtual calprotectin clinic in inflammatory bowel diseases: Literature review and Nancy Experience. J Clin Med. 2020;9(9):2697. doi: 10.3390/jcm9092697
   PubMed Web of Science ®Google Scholar
• Vinding KK, Elsberg H, Thorkilgaard T, et al. Fecal calprotectin measured by patients at home using smartphones—A New clinical tool in monitoring patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(2):336–344. doi: 10.1097/MIB.0000000000000619
   PubMed Web of Science ®Google Scholar
• Heida A, Knol M, Kobold AM, et al. Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity. Clin Gastroenterol Hepatol. 2017;15(11):1742–1749.e2. doi: 10.1016/j.cgh.2017.06.007
   PubMed Web of Science ®Google Scholar
• Ashorov O, Hamouda D, Dickman R, et al. Clinical accuracy of a New rapid Assay for fecal calprotectin measurement. Clin Lab. 2020;66(4/2020):66. doi: 10.7754/Clin.Lab.2020.200126
   Web of Science ®Google Scholar
• Colombel J-F, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779–2789. doi: 10.1016/S0140-6736(17)32641-7
   PubMed Web of Science ®Google Scholar
• Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23(5):577–585. doi: 10.1111/j.1365-2036.2006.02809.x
   PubMed Web of Science ®Google Scholar
• González-Lama Y, Ricart E, Cábez A, et al. Medical consultation in ulcerative colitis: key elements for improvement. World J Gastroenterol. 2023;29(6):917–925. doi: 10.3748/wjg.v29.i6.917
   PubMed Web of Science ®Google Scholar
• Le Berre C, Roda G, Nedeljkovic Protic M, et al. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opin Biol Ther. 2020;20(4):363–378. doi: 10.1080/14712598.2019.1666101
   PubMed Web of Science ®Google Scholar
• Sherlock ME, MacDonald JK, Griffiths AM, et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015;2015(10): 2015:CD007698. doi: 10.1002/14651858.CD007698.pub3
   PubMedGoogle Scholar
• Bonovas S, Nikolopoulos GK, Lytras T, et al. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: systematic review and network meta-analysis. Br J Clin Pharmacol. 2018;84(2):239–251. doi: 10.1111/bcp.13456
   PubMed Web of Science ®Google Scholar
• Gherardi A, Roze S, Kuijvenhoven J, et al. Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands. J Med Econ. 2018;21(9):869–877. doi: 10.1080/13696998.2018.1484371
   PubMed Web of Science ®Google Scholar
• Lofberg R, Danielsson A, Suhr O, et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology. 1996;110(6):1713–1718. doi: 10.1053/gast.1996.v110.pm8964395
   PubMed Web of Science ®Google Scholar
• D’Amico F, Magro F, Siegmund B, et al. Disease clearance as a New outcome in ulcerative colitis: a systematic review and Expert consensus. Inflamm Bowel Dis. 2023. izad159. doi: 10.1093/ibd/izad159
   Web of Science ®Google Scholar
• D’Amico F, Fiorino G, Solitano V, et al. Ulcerative colitis: impact of early disease clearance on long‐term outcomes ‐ a multicenter cohort study. UEG J. 2022;10(7):775–782. doi: 10.1002/ueg2.12288
   PubMed Web of Science ®Google Scholar
• Kruis W, Meszaros S, Wehrum S, et al. Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis. UEG J. 2023;11(8):775–783. ueg2.12435. doi: 10.1002/ueg2.12435
   PubMedGoogle Scholar
• Osterman MT, Aberra FN, Cross R, et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2014;12(11):1887–1893.e3. doi: 10.1016/j.cgh.2014.03.035
   PubMed Web of Science ®Google Scholar
• Buisson A, Mak WY, Andersen MJ, et al. Faecal calprotectin is a very reliable tool to predict and monitor the risk of relapse after therapeutic De-escalation in patients with inflammatory bowel diseases. J Crohns Colitis. 2019;13(8):1012–1024. doi: 10.1093/ecco-jcc/jjz023
   PubMed Web of Science ®Google Scholar
• Lasson A, Öhman L, Stotzer P-O, et al. Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: a prospective, randomized, controlled study. United Eur Gastroenterol J. 2015;3(1):72–79. doi: 10.1177/2050640614560785
   PubMed Web of Science ®Google Scholar
• Goodsall TM, Day AS, Andrews JM, et al. Composite assessment using intestinal ultrasound and calprotectin is accurate in predicting histological activity in ulcerative colitis: a cohort study. Inflamm Bowel Dis. 2023. izad043. doi: 10.1093/ibd/izad043
   PubMed Web of Science ®Google Scholar
• Kawashima K, Oshima N, Kishimoto K, et al. Low fecal calprotectin predicts histological healing in patients with ulcerative colitis with endoscopic remission and leads to prolonged clinical remission. Inflamm Bowel Dis. 2023;29(3):359–366. doi: 10.1093/ibd/izac095
   PubMed Web of Science ®Google Scholar
• Chen J, Girard M, Wang S, et al. Using supervised machine learning approach to predict treatment outcomes of vedolizumab in ulcerative colitis patients. J Biopharm Stat. 2022;32(2):330–345. doi: 10.1080/10543406.2021.2009500
   PubMed Web of Science ®Google Scholar
• Gardiner L-J, Carrieri AP, Bingham K, et al.Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease. PLoS ONE. 2022;17(2):e0263248. doi: 10.1371/journal.pone.0263248
   PubMed Web of Science ®Google Scholar
• Biamonte P, D’Amico F, Fasulo E, et al. New technologies in Digestive endoscopy for ulcerative colitis patients. Biomedicines. 2023;11(8):2139. doi: 10.3390/biomedicines11082139
   PubMed Web of Science ®Google Scholar